Ocular Hypertension clinical trials at UCSF
2 research studies open to eligible people
Clarifying the Optimal Application of SLT Therapy Trial
open to eligible people ages 18 years and up
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
San Francisco, California and other locations
Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
open to eligible people ages 18 years and up
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
San Francisco, California
Our lead scientists for Ocular Hypertension research studies include Julius Oatts, MD Ying Han, MD.
Last updated: